|Table of Contents|

Expression of PD-L1 and sIL-2R in patients with follicular lymphoma and its clinical significance

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2022 02
Page:
303-306
Research Field:
Publishing date:

Info

Title:
Expression of PD-L1 and sIL-2R in patients with follicular lymphoma and its clinical significance
Author(s):
GAN Dingyun; WU Jun; ZHOU Man; LIU Qun
Department of Hematology and Endocrinology,Wuhan Third Hospital (Tongren Hospital of Wuhan University),Hubei Wuhan 430061,China.
Keywords:
PD-L1; sIL-2R; follicular lymphoma; clinical research
PACS:
R733
DOI:
10.3969/j.issn.1672-4992.2022.02.026
Abstract:
Objective：To explore the expression of programmed death-ligand 1 (PD-L1) and soluble interleukin-2 receptor (sIL-2R) in patients with follicular lymphoma and its clinical significance.Methods:From January 2017 to April 2019,82 patients with follicular lymphoma treated in our hospital (42 cases of stage Ⅰ-Ⅱ,40 cases of stage Ⅲ) were selected as observation group,and 10 healthy subjects were selected as control group.The level changes of PD-L1 and sIL-2R in the two groups of subjects were compared and observed.Univariate and multivariate analyses were used to analyse the related factors influencing prognosis of patients with follicular lymphoma.Results:The level of serum sIL-2R and positive expression rate of pathological tissue PD-L1 in the observation group were significantly higher than those in the control group (P＜0.05).The level of serum sIL-2R and positive expression rate of pathological tissue PD-L1 in the observation group Ⅲ stage were higher than those in the observation group Ⅰ-Ⅱ stage (P＜0.05).The cases of PD-L1 positive expression had 13 patients (30.95%),17 patients (42.50%) and 1 patient (10.00%) in the observation group with Ⅰ-Ⅱ stage,Ⅲ stage and control group.Univariate analysis showed that age,international prognostic index,PD-L1 protein and sIL-2R protein expression levels were correlated with prognosis of patients with follicular lymphoma (P＜0.05),but gender,clinical stage,Karnofsky score and with or without symptoms were not related to prognosis (P＞0.05).Cox multivariate analysis showed that the protein expression levels of PD-L1 and sIL-2R were independent prognostic risk factors in patients with follicular lymphoma (P＜0.05).Conclusion:The high expression of PD-L1 in pathological tissues and sIL-2R in serum is a prognostic risk factor for patients with follicular lymphoma,and has clinical guidance value.

References:

[1]刘树梅,李莉娟,张连生.滤泡性淋巴瘤免疫治疗新进展［J］.中国肿瘤生物治疗杂志,2016,23(4):566-570. LIU SM,LI LJ,ZHANG LS.New advances in immunotherapy of follicular lymphoma［J］.Chinese Journal of Cancer Biotherapy,2016,23(4):566-570.
[2]陈紫桂.滤泡性淋巴瘤的发病机制与治疗的研究进展［J］.贵州医药,2016,40(1):94-97. CHEN ZG.Research progress in the pathogenesis and treatment of follicular lymphoma［J］.Guizhou Medical Journal,2016,40(1):94-97.
[3]王楠,赵维莅.基于分子异质性的滤泡性淋巴瘤诊治进展［J］.临床血液学杂志,2018,31(5):14-19. WANG N,ZHAO WL.Progress in diagnosis and treatment of follicular lymphoma based on molecular heterogeneity［J］.Journal of Clinical Hematology,2018,31(5):14-19.
[4]中华医学会血液学分会,中国抗癌协会淋巴瘤专业委员会.中国滤泡性淋巴瘤诊断与治疗指南(2013年版)［J］.中华血液学杂志,2013,34(9):820-824. Chinese Society of Hematology,Chinese Medical Association/Chinese Society of Lymphoma,Chinese Anti-cancer Association.China' s diagnosis and treatment of follicular lymphoma guide (2013 edition)［J］.Chinese Journal of Hematology,2013,34(9):820-824.
[5]张芬,罗东兰,骆新兰,等.HGAL及LMO2在滤泡性淋巴瘤中的表达及其意义［J］.中华病理学杂志,2016,45(2):83-85. ZHANG F,LUO DL,LUO XL,et al.Expression and significance of HGAL and LMO2 in follicular lymphoma［J］.Chinese Journal of Pathology,2016,45(2):83-85.
[6]金静霞,郑翠苹,陈丽雅,等.PD-1、PD-L1在弥漫大B细胞淋巴瘤组织中的差异性表达及其临床意义［J］.临床血液学杂志,2018,31(1):34-37. JIN JX,ZHENG CP,CHEN LY,et al.Differential expression of PD-1 and PD-L1 in diffuse large B-cell lymphoma and its clinical significance［J］.Journal of Clinical Hematology,2018，31(1):34-37.
[7] KOO M,OHGAMI RS.Pediatric-type follicular lymphoma and pediatric nodal marginal zone lymphoma:recent clinical,morphologic,immunophenotypic,and genetic insight［J］.Advances in Anatomic Pathology,2017,24(3):128-135.
[8]马玉青,杨晓婷.利妥昔单抗在B细胞非霍奇金淋巴瘤治疗中的应用效果［J］.河南医学研究,2020,29(22):4096-4098. MA YQ,YANG XT.Effect of rituximab in the treatment of B-cell non-Hodgkin's lymphoma［J］.Henan Med Res,2020,29(22):4096-4098.
[9]董玲,吕慧娟,孔令喆,等.PD-1/PD-L1通路在恶性淋巴瘤中的研究进展［J］.中华微生物学和免疫学杂志,2015,35(10):789-792. DONG L,LYU HJ,KONG LZ,et al.Research progress of PD-1/PD-L1 pathway in malignant lymphoma［J］.Chinese Journal of Microbiology and Immunology,2015,35(10):789-792.
[10]AARON G,SANDIP P,RAZELLE KURZROCK.PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas［J］.Nature Reviews Clinical Oncology,2016,14(4):203-220.
[11]曲通,周雪萌,刘海石,等.免疫检查点抑制剂在恶性淋巴瘤中的应用研究进展［J］.中国肿瘤临床,2016,43(20):922-926. QU T,ZHOU XM,LIU HS,et al.Research progress on the application of immune checkpoint inhibitors in malignant lymphoma［J］.Chinese Journal of Clinical Oncology,2016,43(20):922-926.
[12]顾科峰,陆静忠,宋超英.非霍奇金淋巴瘤患者血清可溶性白细胞介素-2受体检测及意义［J］.国际检验医学杂志,2017,38(6):777-780. GU KF,LU JZ,SONG CY.Detection and significance of serum soluble interleukin-2 receptor in patients with non-Hodgkin's lymphoma［J］.Journal of International Laboratory Medicine,2017,38(6):777-780.
[13]张杰,蒋依憬,徐小红.弥漫性大B细胞淋巴瘤血清生物标志物的研究进展［J］.中国肿瘤临床,2019,46(23):1218-1222. ZHANG J,JIANG YJ,XU XH.Advances in serum biomarkers for diffuse large B-cell lymphoma［J］.Chin J Chin Oncol,2019,46(23):1218-1222.
[14]CARRERAS J,LOPEZ-GUILLERMO A,KIKUTI YY,et al.High TNFRSF14 and low BTLA are associated with poor prognosis in follicular lymphoma and in diffuse large B-cell lymphoma transformation［J］.J Chin Exp Hematop,2019,59(1):1-16.
[15]魏征，施淼颉，邹善华.合并乙型肝炎病毒感染对弥漫大B细胞淋巴瘤患者血清TNF-α、sIL-2r、IL-6及IL-10水平的影响［J］.中国临床医学,2017,24(3):343-347. WEI Z,SHI MJ,ZOU SH.Effects of combined hepatitis B virus infection on serum TNF-α,sIL-2r,IL-6 and IL-10 levels in patients with diffuse large B-cell lymphoma［J］.Chinese Journal of Clinical Medicine,2017,24(3):343-347.

Memo

Memo:
-
Last Update: 1900-01-01